Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and Complications.
코호트
2/5 보강
OpenAlex 토픽 ·
Potassium and Related Disorders
Cancer Immunotherapy and Biomarkers
Esophageal Cancer Research and Treatment
[OBJECTIVES] We characterized features of immune checkpoint inhibitor (ICI) esophagitis.
APA
Matthew J. Townsend, Afeerah Mumtaz, et al. (2026). Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and Complications.. Clinical and translational gastroenterology. https://doi.org/10.14309/ctg.0000000000001035
MLA
Matthew J. Townsend, et al.. "Immune Checkpoint Inhibitor Esophagitis: Clinical and Endoscopic Presentation, Treatment Outcomes, and Complications.." Clinical and translational gastroenterology, 2026.
PMID
41944490 ↗
Abstract 한글 요약
[OBJECTIVES] We characterized features of immune checkpoint inhibitor (ICI) esophagitis.
[METHODS] Retrospective cohort of biopsy-confirmed ICI esophagitis.
[RESULTS] Among 11,636 ICI-treated adults, 22/312 (7%) undergoing EGD had ICI esophagitis (0.2% overall). Concomitant luminal ICI toxicities occurred in 19/22 (86%); 8/22 (36%) had normal esophageal appearance. Most experienced symptom resolution with acid suppression, steroids, and/or biologic therapy; however, one developed refractory strictures.
[CONCLUSIONS] ICI esophagitis is rare, often coexists with other gastrointestinal toxicities, and may appear endoscopically normal, underscoring importance of biopsies. Symptoms are typically treatment-responsive, but histologic inflammation can persist. Rare severe complications highlight needs for recognition and tailored therapy.
[METHODS] Retrospective cohort of biopsy-confirmed ICI esophagitis.
[RESULTS] Among 11,636 ICI-treated adults, 22/312 (7%) undergoing EGD had ICI esophagitis (0.2% overall). Concomitant luminal ICI toxicities occurred in 19/22 (86%); 8/22 (36%) had normal esophageal appearance. Most experienced symptom resolution with acid suppression, steroids, and/or biologic therapy; however, one developed refractory strictures.
[CONCLUSIONS] ICI esophagitis is rare, often coexists with other gastrointestinal toxicities, and may appear endoscopically normal, underscoring importance of biopsies. Symptoms are typically treatment-responsive, but histologic inflammation can persist. Rare severe complications highlight needs for recognition and tailored therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.